Trial Profile
A Prospective Single Center Trial To Evaluate The Efficacy Of Ledipasvir/ Sofosbuvir (Harvoni)± Ribavirin Versus Ombitasvir/Paritavir/Ritonavir/Dasubuvir (Viekira Pak)± Ribavirin In Treatment-Naive And Experienced Genotype 1 Hepatitis C Virus Infected US Veterans.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 13 May 2016 New trial record
- 17 Apr 2016 Results (n=132) of SVR12 data until November 2015 were presented at The International Liver Congress™ 2016.